- Active not recruitingPHASE2
Long-term Study Evaluating the Effect of Givinostat in Patients With Chronic Myeloproliferative Neoplasms
This study looks at how safe and effective Givinostat is over a long time for people with certain blood conditions (Myeloproliferative Neoplasms). It checks safety, how well patients tolerate it, and if it helps them, for those already taking the drug.
For: Chronic Myeloproliferative NeoplasmsGermany · Italy · United Kingdom - RecruitingPHASE2, PHASE3
Givinostat in Duchenne's Muscular Dystrophy Long-term Safety and Tolerability Study
This study looks at the long-term safety and effects of a medicine called Givinostat for boys with Duchenne muscular dystrophy. It's for those who have already taken Givinostat in a previous study to see how it helps over time.
For: Duchenne Muscular DystrophyUnited States · Belgium · Canada - RecruitingPHASE3
Efficacy, Safety and Tolerability of Givinostat in Non-ambulant Patients With Duchenne Muscular Dystrophy
This study is testing a new medicine, Givinostat, for boys aged 9-17 with Duchenne muscular dystrophy who use a wheelchair. Researchers want to see if it helps reduce muscle decline and is safe to use. Half the boys will get the medicine, and half a dummy pill for 18 months.
For: Duchenne Muscular DystrophyBelgium · Canada · Czechia - RecruitingPHASE3
Study on Efficacy and Safety of Givinostat Versus Hydroxyurea in Patients With Polycythemia Vera
This study compares two treatments, givinostat and hydroxyurea, for polycythemia vera (PV). It aims to see how well they work and if they are safe for patients with a high risk of blood clots. It focuses on PV caused by a specific gene change (JAK2V617F).
For: Polycythemia VeraUnited States · Austria · Bulgaria